TickerTalks
Browse all tickers →
TickerTalks›$LAB
LALAB

Standard BioTools Inc.

$LAB·$270M·Medical - Specialties·Healthcare
$0.63-4.5%YTD-48.1%1Y-53.0%
Price updated 13m ago·X counts updated 5d ago
LALAB
$LABStandard BioTools Inc.
$0.63-4.47%477 posts1.3×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $LAB on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

477X posts · last 7 days
Sep 28Oct 11
Chatter Meter
1.3×
QuietNormal · 1×Loud

How loud $LAB's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 92% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data7 posts analyzed · as of 2026-10-02

The $LAB feed is a Solana-adjacent memecoin — bulls are flagging LAB in the "BR / AKE / ONE / RARE / SAGA / BTW" set that each had a 50x pump, with large players reportedly pulling LAB off exchanges as the setup trigger. The thread is pure "next hidden gem" shilling and influencer self-promotion. One voice admits LAB "has pumped enough already, maybe it's time to wrap things up."

Read what X is saying about $LAB

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $LAB — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Broken storySelling offAI verdict · as of 2026-10-02

Falling on heavy selling — points lower unless it turns around.

Standard BioTools is a sub-$1 life-sciences tools name bleeding money — the X thread is about a different pump entirely.

Standard BioTools makes life-sciences instruments and consumables — the merged entity formed when Fluidigm absorbed SomaLogic in 2024. Revenue has barely grown and operating losses are deep, and the equity has slid into penny-stock territory.

  • Revenue grew just 4.6% YoY last quarter at a -91% operating margin — the two-brand integration has not delivered revenue synergies, and the cash burn is accelerating against a $290M market cap.
  • 52-week range position is 9% with the stock at $0.73 — this is penny-stock territory where the risk of a reverse split or going-concern language is a near-term consideration.
  • At 5.2x sales the name does not look cheap for a company burning cash at this pace — the valuation is still pricing in a return to meaningful growth that has not shown up in two years of merger integration.

Nov 3 earnings is the test — a credible path to cash-burn reduction plus any evidence that proteomics is finally scaling can get the stock off the floor. Another soft print and this slides toward going-concern language and sub-$0.50.

What to watch: Nov 3 Q3 — proteomics revenue trajectory, cash burn, and any update on reverse-split or going-concern commentary. A new dilutive raise is the hard invalidator.

On the calendar: 2026-11-03 — Q3 earnings

cashtag collision

Read the AI verdict on $LAB

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Life science tools company offering microfluidics and mass cytometry instruments for drug discovery research.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Specialties sits in its cycle right now — and what that implies for $LAB.

Medical - Specialties · Healthcare

Post-COVID procedure volume normalization has largely completed; growth now driven by aging demographics and incremental adoption of AI-assisted diagnostic imaging (radiology AI, pathology AI). Reimbursement rate adjustments from CMS and commercial payer contract cycles are the near-term margin variable.

What this means for $LAB

Neutral — Life science tools company offering microfluidics and mass cytometry instruments for drug discovery research.

Top industry ETF

$XLVHealth Care Select Sector SPDR
+9.0%YTD
+24.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-4.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-7.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-91.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-21.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.2Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-20.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
48.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$-0.07$-0.01-449.0%
Q1 2026May 5, 2026$-0.02$-0.020.0%
Q4 2025Feb 24, 2026$0.06$-0.03+300.0%
Q3 2025Nov 4, 2025$-0.09$-0.04-107.7%
Next earningsTue, Nov 3·consensus EPS $-0.02

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$21.1M+4.6%53.5%-44.5%$-0.12$-47.2M
Q4 FY25$23.8M-49.1%43.0%-92.1%$0.05$-1.7M
Q3 FY25$19.6M-56.5%48.5%-120%$-0.09$-23.1M
Q2 FY25$21.8M-3.2%48.8%-109%$-0.09$-22.6M

Forward consensus

4-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$82.5M$82.5M – $82.5M-$0.10-$0.10 – -$0.101
FY27$82.1M$82.1M – $82.1M-$0.16-$0.16 – -$0.161
FY28$85.7M$85.7M – $85.7M-$0.14-$0.14 – -$0.141
FY29$89.4M$89.4M – $89.4M-$0.15-$0.15 – -$0.151

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.3%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-6.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-31.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 42.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.355-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 15 other (8 inkinds · 7 awards) in window

See when $LAB insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDOct 58-K — Item 7.01: Press release / Reg FD
8-KAgreement terminatedSep 308-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated · Item 7.01: Press release / Reg FD
8-KPress release / Reg FDAug 58-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Standard BioTools Inc. (LAB) reported Q2 2026 financial results on 2026-08-05, reporting results detailed in attached press release. Management guidance: Outlook” and “About Standard BioTools Inc. Additional items: Item 7.01. Quarterly earnings are a material disclosure; investors should review the full press release for segment details and management commentary.

8-KMaterial agreementJul 288-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

Standard BioTools Inc. (LAB) entered into a Termination, Waiver and Release Agreement with Illumina, Inc. on July 24, 2026, receiving approximately $30 million in cash in exchange for waiving and releasing future earnout and royalty payment obligations related to SomaScan assay services, SOMAmer-based array kits, and next-generation sequencing library prep kits. The related royalty and license agreements (from January 30, 2026 in connection with Illumina's purchase of the SomaScan business) were also terminated. Receiving $30M upfront to terminate future contingent revenue streams represents a risk/liquidity trade-off; the materiality depends on how probable those future royalties were.

8-KListing / delisting noticeJul 248-K — Item 3.01: Listing / delisting notice
AI summary

LAB filed an 8-K covering Item(s) 3.01. Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On July 22, 2026, Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) indicating that the Company did not meet the minimum bid price requirement set forth in Nasdaq’s Listing Rules for continued listing on The Nasdaq Global Select Market. . Investors should review the full filing for complete details.

8-KOfficer or director changeJun 188-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Standard BioTools (LAB) held its 2026 Annual Meeting on June 17, 2026 with 390,368,119 shares outstanding. Shareholders approved a new 2026 Equity Incentive Plan and an amendment to the Employee Stock Purchase Plan adding 1,200,000 shares in aggregate. Routine director elections and other governance proposals also passed. No extraordinary compensation or structural changes were disclosed.

SC 13DActivist position (5%+)Jun 12SC 13D
AI summary

Viking Global Investors LP filed an initial Schedule 13D on Standard BioTools Inc. (LAB) as of June 6, 2026, disclosing beneficial ownership of approximately 39,296,310 shares representing 15% of the class (via Viking Global Investors LP) and 10.1% (via the Viking Global Opportunities sub-entities). An initial 13D (rather than passive 13G) from a major hedge fund signals active engagement intent — Viking may seek to influence strategy, governance, or M&A at the life-science tools company.

SC 13D/AActivist amendmentJun 9SC 13D/A
AI summary

Casdin Capital, LLC (investment adviser) filed Amendment No. 8 to Schedule 13D on June 9, 2026, disclosing a 22.7% aggregate beneficial ownership stake (88,783,856 shares) in Standard BioTools Inc. (LAB) as of June 6, 2026. The group includes Casdin Partners Master Fund, Casdin Private Growth Equity Fund II (3.6%), and related entities. The filing is an amendment reflecting updated share counts; at 22.7% with shared voting and dispositive power, Casdin remains the dominant activist/strategic holder and any position changes or engagement disclosures would be highly material to LAB.

+ 30 other (7 425s · 5 13Gs · 5 8-Ks · 2 S-4/As) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMEDglobenewswire.com·11d agoStandard BioTools Provides Update on Sale of Mass Cytometry Businessglobenewswire.com·16d agoAre SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?gurufocus.com·35d agoAre SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?prnewswire.com·35d ago$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Proxy and Looming Shareholder Merger Vote --VRME, VAL, LAB and FTHMgurufocus.com·36d ago

More in Medical - Specialties

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$STE$ALC
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport